Login to Your Account



Pediatric ODAC Panel Wrestles with New Cancer Paradigm

By Mari Serebrov
Washington Editor

Tuesday, November 5, 2013
All the hurdles in developing drugs to fight cancer in children came to the fore as the Pediatric Oncology Subcommittee of the FDA’s Oncology Drugs Advisory Committee grappled with the unknowns of science and a pressing unmet need as they discussed development plans for Bristol-Myers Squibb Co.’s nivolumab, Merck Sharp and Dohme’s MK-3475 and Novartis Pharmaceuticals Corp.’s LEE011.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription